- Conditions
- Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions
- Interventions
- data collection
- Drug
- Lead sponsor
- Paul Szabolcs
- Other
- Eligibility
- 2 Months to 60 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–85
of 85
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hematologic Malignancies, Nonmalignant Diseases, Immunodeficiencies, Hemoglobinopathies, Genetic Inborn Errors of Metabolism, Fanconi Anemia, Thalassemia, Sickle Cell Disease
- Interventions
- Fludarabine
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Sickle Cell Disease
- Interventions
- WE CARE SDoH Screening Survey, Family Resource Book, Standard of care
- Behavioral · Other
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Sickle Cell Disease
- Interventions
- Voxelotor
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 13
- States / cities
- Brentwood, California • Washington D.C., District of Columbia • Atlanta, Georgia + 9 more
- Conditions
- Sickle Cell Anemia
- Interventions
- ACZ885, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 8 Years to 20 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Augusta, Georgia • Greenville, North Carolina
- Conditions
- Sickle Cell Disease
- Interventions
- Voxelotor
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 6 Months to 11 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • San Diego, California • Wilmington, Delaware + 20 more
- Conditions
- Sickle Cell Disease
- Interventions
- Single Session Problem-Solving Intervention
- Behavioral
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Nocturnal Enuresis, Anemia, Sickle Cell
- Interventions
- Desmopressin
- Drug
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 8 Years to 21 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Sickle Cell Disease (SCD), Sickle Cell Disease Vaso-occlusive Crisis, Sickle Cell Anemia Crisis, Sickle Cell Anemia in Children, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Sickle Cell Hemoglobin C Disease, Pain Crisis
- Interventions
- Buprenorphine Buccal Film [Belbuca]
- Drug
- Lead sponsor
- Natasha Archer
- Other
- Eligibility
- 12 Years to 22 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Child, Only, Brain Diseases, Sickle Cell Disease, Anemia, Sickle Cell
- Interventions
- Carbon Dioxide
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 4 Years to 21 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Sickle Cell Crisis
- Interventions
- Virtual Reality Goggles
- Other
- Lead sponsor
- University of Mississippi Medical Center
- Other
- Eligibility
- 6 Years to 21 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Jackson, Mississippi
- Conditions
- Atypical Hemolytic Uremic Syndrome
- Interventions
- Crovalimab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 28 Days to 17 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Omaha, Nebraska • Hackensack, New Jersey
- Conditions
- Thrombotic Microangiopathy, Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura
- Interventions
- Not listed
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- New Hyde Park, New York